Table of Content

1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Project Objectives
1.4. Scope of the Report
1.5. Inclusions and Exclusions
1.6. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates
3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry
3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION
5.1. Chapter Overview
5.2. Traditional Clinical Trials versus Decentralized Clinical Trials
5.3. Need of Decentralized Clinical Trials
5.3.1. Increasing Trial Costs and Complexity
5.3.2. Evolving Regulatory Standards
5.3.3. Patient Recruitment / Retention-related Challenges
5.3.4. Inefficient Data Handling
5.4. Decentralized Clinical Trials
5.4.1. Modes of Decentralized Clinical Trials
5.4.1.1. Fully Virtual Decentralized Clinical Trials
5.4.1.2. Hybrid Decentralized Clinical Trials
5.5. Applications of Decentralized Clinical Trials
5.6. Emerging Trends in Clinical Drug Development
5.6.1. Innovative Trial Designs
5.6.2. Real-world Evidence
5.6.3. Patient-centricity
5.6.4. Big Data Analytics
5.6.5. Blockchain Technology
5.7. Challenges Associated with Decentralized Clinical Trials
5.8. Future Perspectives

6. MARKET LANDSCAPE
6.1. Chapter Overview
6.2. Decentralized Clinical Trials Service Providers: Overall Market Landscape
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Company Size
6.2.3. Analysis by Location of Headquarters (Region)
6.2.4. Analysis by Location of Headquarters (Country)
6.2.5. Analysis by Company Size and Location of Headquarters (Region)
6.2.6. Analysis by Key Offering
6.2.7. Analysis by Compliance
6.2.8. Analysis by Mode of Decentralized Clinical Trial
6.2.9. Analysis by Type of Capability
6.2.10. Analysis by Mode of Decentralized Clinical Trial and Type of Capability
6.2.11. Analysis by Therapeutic Area
6.2.12. Analysis by Mode of Decentralized Clinical Trial and Therapeutic Area
6.2.13. Analysis by Trial Phase

7. COMPANY PROFILES
7.1. Chapter Overview
7.2. Detailed Company Profiles of Key Players
7.2.1. Fortrea
7.2.1.1. Company Overview
7.2.1.2. Decentralized Clinical Trial Offerings
7.2.1.3. Recent Developments and Future Outlook
7.2.2. IQVIA
7.2.2.1. Company Overview
7.2.2.2. Financial Information
7.2.1.2. Decentralized Clinical Trial Offerings
7.2.1.3. Recent Developments and Future Outlook
7.2.3. KORE Wireless
7.2.3.1. Company Overview
7.2.3.2. Financial Information
7.2.3.3. Decentralized Clinical Trial Offerings
7.2.3.4. Recent Developments and Future Outlook
7.2.4. Labcorp
7.2.4.1. Company Overview
7.2.4.2. Financial Information
7.2.4.3. Decentralized Clinical Trial Offerings
7.2.4.4. Recent Developments and Future Outlook
7.2.5. Medpace
7.2.5.1. Company Overview
7.2.5.2. Financial Information
7.2.5.3. Decentralized Clinical Trial Offerings
7.2.5.4. Recent Developments and Future Outlook
7.2.6. Parexel
7.2.6.1. Company Overview
7.2.6.2. Decentralized Clinical Trial Offerings
7.2.6.3. Recent Developments and Future Outlook
7.2.7. PPD
7.2.7.1. Company Overview
7.2.7.2. Financial Information
7.2.7.3. Decentralized Clinical Trial Offerings
7.2.7.4. Recent Developments and Future Outlook
7.2.8. Syneos Health
7.2.8.1. Company Overview
7.2.8.2. Financial Information
7.2.8.3. Decentralized Clinical Trial Offerings
7.2.8.4. Recent Developments and Future Outlook
7.2.9. Signant Health
7.2.9.1. Company Overview
7.2.9.2. Decentralized Clinical Trial Offerings
7.2.9.3. Recent Developments and Future Outlook
7.2.10. Veeva
7.2.10.1. Company Overview
7.2.10.2. Financial Information
7.2.10.3. Decentralized Clinical Trial Offerings
7.2.10.4. Recent Developments and Future Outlook
7.2.11. Cambridge Cognition
7.2.11.1. Company Overview
7.2.11.2. Financial Information
7.2.11.3. Decentralized Clinical Trial Offerings
7.2.11.4. Recent Developments and Future Outlook
7.2.12. Medidata Solutions
7.2.12.1. Company Overview
7.2.12.2. Financial Information
7.2.12.3. Decentralized Clinical Trial Offerings
7.2.12.4. Recent Developments and Future Outlook
7.2.13. PanAmerican Clinical Research
7.2.13.1. Company Overview
7.2.13.2. Decentralized Clinical Trial Offerings
7.2.13.3. Recent Developments and Future Outlook
7.2.14. Science 37
7.2.14.1. Company Overview
7.2.14.2. Financial Information
7.2.14.3. Decentralized Clinical Trial Offerings
7.2.14.4. Recent Developments and Future Outlook
7.3. Short Profiles of Other Prominent Players
7.3.1. Aardex
7.3.1.1. Company Overview
7.3.1.2. Decentralized Clinical Trial Offerings
7.3.2. CareShare
7.3.2.1. Company Overview
7.3.2.2. Decentralized Clinical Trial Offerings
7.3.3. Clariness
7.3.3.1. Company Overview
7.3.3.2. Decentralized Clinical Trial Offerings
7.3.4. Cliniv
7.3.4.1. Company Overview
7.3.4.2. Decentralized Clinical Trial Offerings

7.3.5. Clinscience
7.3.5.1. Company Overview
7.3.5.2. Decentralized Clinical Trial Offerings
7.3.6. CMIC
7.3.6.1. Company Overview
7.3.6.2. Decentralized Clinical Trial Offerings
7.3.7. DynamiQ Health
7.3.7.1. Company Overview
7.3.7.2. Decentralized Clinical Trial Offerings
7.3.8. Emovis
7.3.8.1. Company Overview
7.3.8.2. Decentralized Clinical Trial Offerings
7.3.9. Ergomed
7.3.9.1. Company Overview
7.3.9.2. Decentralized Clinical Trial Offerings
7.3.10. Flatworld Solutions
7.3.10.1. Company Overview
7.3.10.2. Decentralized Clinical Trial Offerings
7.3.11. Gsap
7.3.11.1. Company Overview
7.3.11.2. Decentralized Clinical Trial Offerings
7.3.12. Guild
7.3.12.1. Company Overview
7.3.12.2. Decentralized Clinical Trial Offerings
7.3.13. Hexaware Technologies
7.3.13.1. Company Overview
7.3.13.2. Decentralized Clinical Trial Offerings
7.3.14. Huma
7.3.14.1. Company Overview
7.3.14.2. Decentralized Clinical Trial Offerings
7.3.15. ICON
7.3.15.1. Company Overview
7.3.15.2. Decentralized Clinical Trial Offerings
7.3.16. Kayentis
7.3.16.1. Company Overview
7.3.16.2. Decentralized Clinical Trial Offerings
7.3.17. Tata Consultancy Services
7.3.17.1. Company Overview
7.3.17.2. Decentralized Clinical Trial Offerings
7.3.18. Viedoc
7.3.18.1. Company Overview
7.3.18.2. Decentralized Clinical Trial Offerings
7.3.19. WeGuide
7.3.19.1. Company Overview
7.3.19.2. Decentralized Clinical Trial Offerings
7.3.20. Wren Healthcare
7.3.20.1. Company Overview
7.3.20.2. Decentralized Clinical Trial Offerings
8. COMPANY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Methodology
8.4. Competitiveness Analysis: Companies based in North America
8.5. Competitiveness Analysis: Companies based in Europe
8.6. Competitiveness Analysis: Companies based in Asia-Pacific and Rest of the World
9. CLINICAL TRIAL ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Decentralized Clinical Trials
9.3.1. Analysis by Trial Registration Year
9.3.2. Analysis by Number of Patients Enrolled
9.3.3. Analysis by Trial Phase
9.3.4. Analysis by Trial Registration Year and Trial Phase
9.3.5. Analysis by Patients Enrolled and Trial Phase
9.3.6. Analysis by Trial Status
9.3.7. Analysis by Trial Registration Year and Trial Status
9.3.8. Analysis by Target Patient Population
9.3.9. Analysis by Patient Gender
9.3.10. Analysis by Therapeutic Area
9.3.11. Analysis by Type of Sponsor / Collaborator
9.3.12. Word Cloud Analysis: Emerging Focus Areas
9.3.13. Analysis by Study Design
9.3.13.1. Analysis by Type of Patient Allocation Model Used
9.3.13.2. Analysis by Type of Trial Masking Adopted
9.3.13.3. Analysis by Type of Intervention
9.3.13.4. Analysis by Trial Purpose
9.3.14. Most Active Players: Analysis by Number of Clinical Trials
9.3.15. Analysis by Geography
9.3.15.1. Analysis of Clinical Trials by Geography
9.3.15.2. Analysis of Clinical Trials by Geography and Trial Status
9.3.15.3. Analysis of Patients Enrolled by Geography and Trial Status

10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Decentralized Clinical Trials: Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Year and Type of Partnership
10.3.4. Analysis by Type of Partner
10.3.5. Analysis by Year of Partnership and Type of Partner
10.3.6. Analysis by Type of Partnership and Type of Partner
10.3.7. Analysis by Type of Capability
10.3.8. Analysis by Type of Partnership and Type of Capability
10.3.9. Most Active Players: Analysis by Number of Partnerships
10.3.10. Analysis by Geography
10.3.10.1. Local and International Agreements
10.3.10.2. Intracontinental and Intercontinental Agreements

11. FUNDING AND INVESTMENTS
11.1. Chapter Overview
11.2. Funding Models
11.3. Decentralized Clinical Trials: Funding and Investments
11.3.1. Analysis by Year of Funding
11.3.2. Analysis by Amount Invested
11.3.3. Analysis by Type of Funding
11.3.4. Analysis by Year and Type of Funding
11.3.5. Analysis by Type of Funding and Amount Invested
11.3.6. Analysis by Geography
11.3.8. Most Active Players: Analysis by Number of Funding Instances
11.3.9. Most Active Players: Analysis by Amount Raised
11.3.10. Leading Investors: Analysis by Number of Funding Instances
11.4. Concluding Remarks

12. CASE STUDY: DECENTRALIZED CLINICAL TRIAL-RELATED INITIATIVES OF BIG PHARMA COMPANIES
12.1. Chapter Overview
12.2. Decentralized Clinical Trial-related Initiatives of Big Pharma Companies
12.2.1. Pfizer
12.2.1.1. Decentralized Clinical Trial-related Initiatives
12.2.1.2. Future Perspective
12.2.2. Amgen
12.2.2.1. Decentralized Clinical Trial-related Initiatives
12.2.2.2. Future Perspective
12.2.3. AstraZeneca
12.2.3.1. Decentralized Clinical Trial-related Initiatives
12.2.3.2. Future Perspective
12.2.4. GlaxoSmithKline
12.2.4.1. Decentralized Clinical Trial-related Initiatives
12.2.4.2. Future Perspective
12.2.5. Johnson & Johnson
12.2.5.1. Decentralized Clinical Trial-related Initiatives
12.2.5.2. Future Perspective
12.2.6. Novartis
12.2.6.1. Decentralized Clinical Trial-related Initiatives
12.2.6.2. Future Perspective
12.2.7. Sanofi
12.2.7.1. Decentralized Clinical Trial-related Initiatives
12.2.7.2. Future Perspective

13. CASE STUDY: TRADITIONAL VERSUS DECENTRALIZED CLINICAL TRIALS
13.1. Chapter Overview
13.2. Comparison between Traditional and Decentralized Clinical Trials
13.3. Key Attributes of Decentralized Clinical Trials
13.4. Decentralized Operating Models
13.5. Concluding Remarks

14. CASE STUDY: COVID-19 IMPACT
14.1. Chapter Overview
14.2. Impact of COVID-19 on Clinical Trials
14.3. Impact of COVID-19 on Future Opportunity for Decentralized Clinical Trial Companies

15. COST SAVING ANALYSIS
15.1. Chapter Overview
15.2. Key Assumptions and Methodology
15.3. Overall Cost Saving Potential of Decentralized Clinical Trials, 2023-2035
15.3.1. Cost Saving Potential: Distribution by Key Geographical Regions, 2023 and 2035
15.3.1.1. Cost Saving Potential in North America, 2023-2035
15.3.1.1.1. Cost Saving Potential in Phase I Clinical Trials, 2023-2035
15.3.1.1.2. Cost Saving Potential in Phase II Clinical Trials, 2023-2035
15.3.1.1.3. Cost Saving Potential in Phase III Clinical Trials, 2023-2035
15.3.1.1.4. Cost Saving Potential in Phase IV Clinical Trials, 2023-2035
15.3.1.2. Cost Saving Potential in Europe, 2023-2035
15.3.1.2.1. Cost Saving Potential in Phase I Clinical Trials, 2023-2035
15.3.1.2.2. Cost Saving Potential in Phase II Clinical Trials, 2023-2035
15.3.1.2.3. Cost Saving Potential in Phase III Clinical Trials, 2023-2035
15.3.1.2.4. Cost Saving Potential in Phase IV Clinical Trials, 2023-2035
15.3.1.3. Cost Saving Potential in Asia-Pacific, 2023-2035
15.3.1.3.1. Cost Saving Potential in Phase I Clinical Trials, 2023-2035
15.3.1.3.2. Cost Saving Potential in Phase II Clinical Trials, 2023-2035
15.3.1.3.3. Cost Saving Potential in Phase III Clinical Trials, 2023-2035
15.3.1.3.4. Cost Saving Potential in Phase IV Clinical Trials, 2023-2035
15.3.1.4. Cost Saving Potential in Middle East and North Africa, 2023-2035
15.3.1.4.1. Cost Saving Potential in Phase I Clinical Trials, 2023-2035
15.3.1.4.2. Cost Saving Potential in Phase II Clinical Trials, 2023-2035
15.3.1.4.3. Cost Saving Potential in Phase III Clinical Trials, 2023-2035
15.3.1.4.4. Cost Saving Potential in Phase IV Clinical Trials, 2023-2035
15.3.1.5. Cost Saving Potential in Latin America, 2023-2035
15.3.1.5.1. Cost Saving Potential in Phase I Clinical Trials, 2023-2035
15.3.1.5.2. Cost Saving Potential in Phase II Clinical Trials, 2023-2035
15.3.1.5.3. Cost Saving Potential in Phase III Clinical Trials, 2023-2035
15.3.1.5.4. Cost Saving Potential in Phase IV Clinical Trials, 2023-2035
15.4. Conclusion

16. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
16.1. Chapter Overview
16.2. Market Drivers
16.3. Market Restraints
16.4. Market Opportunities
16.5. Market Challenges
16.6. Conclusion

17. GLOBAL DECENTRALIZED CLINICAL TRIALS MARKET
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Global Decentralized Clinical Trials Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
17.3.1. Scenario Analysis
17.3.1.1. Conservative Scenario Analysis
17.3.1.2. Optimistic Scenario Analysis
17.4. Key Market Segmentations
17.5. Dynamic Dashboards

18. DECENTRALIZED CLINICAL TRIALS MARKET, BY MODE OF DECENTRALIZED CLINICAL TRIAL
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Decentralized Clinical Trials Market: Distribution by Mode of Decentralized Clinical Trial, 2023 and 2035
18.4. Hybrid Clinical Trials: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.5. Fully Virtual Clinical Trials: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.6. Data Triangulation and Validation
19. DECENTRALIZED CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Decentralized Clinical Trials Market: Distribution by Therapeutic Area, 2023 and 2035
19.4. Cardiovascular Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.5. Infectious Diseases: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.6. Metabolic Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.7. Neurological Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.8. Oncological Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.9. Respiratory Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.10. Other Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.11. Data Triangulation and Validation
20. DECENTRALIZED CLINICAL TRIALS MARKET, BY TRIAL PHASE
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Decentralized Clinical Trials Market: Distribution by Trial Phase, 2023 and 2035
20.4. Phase I: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
20.5. Phase II: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
20.6. Phase III: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
20.7. Phase IV: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
20.8. Data Triangulation and Validation
21. DECENTRALIZED CLINICAL TRIALS MARKET, BY COMPANY SIZE
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Decentralized Clinical Trials Market: Distribution by Company Size, 2023 and 2035
21.4. Small Companies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
21.5. Mid-sized Companies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
21.6. Large Companies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
21.7. Data Triangulation and Validation
22. DECENTRALIZED CLINICAL TRIALS MARKET, BY END-USER
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Decentralized Clinical Trials Market: Distribution by End-user, 2023 and 2035
22.4. Pharmaceutical and Biotechnology Companies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
22.5. Academic and Research Institutes: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
22.6. Medical Device Industries: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
22.7. Other End-users: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
22.8. Data Triangulation and Validation
23. DECENTRALIZED CLINICAL TRIALS MARKET, BY KEY GEOGRAPHICAL REGION
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Decentralized Clinical Trials Market: Distribution by Key Geographical Regions, 2023 and 2035
23.4. North America: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
23.5. Europe: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
23.6. Asia-Pacific: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
23.7. Middle East and North Africa: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
23.8. Latin America: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
23.9. Data Triangulation and Validation
24. CONCLUSION
25. EXECUTIVE INSIGHTS
25.1. Chapter Overview
25.2. Allucent
25.2.1. Interview Transcript: Mark Goldberg (Chief Executive Officer)
25.3. Andaman7
25.3.1. Interview Transcript: Vincent Keumen (Chief Executive Officer and Founder)
25.4. Clariness
25.4.1. Interview Transcript: Richard Higgins (Director Business Development)
25.5. Delve Health
25.5.1. Interview Transcript: Tim Davies (Executive Director)
25.6. Encapsia
25.6.1. Interview Transcript: Chris Tetley (Senior Manager Business Development)
25.7. FindMeCure
25.7.1. Interview Transcript: Ralitsa Vaskova (Head of Operations)
25.8. MedPoint Digital
25.8.1. Interview Transcript: Bill Cooney (Chief Innovation Officer and President)
25.9. RegAsk
25.9.1. Interview Transcript: Ronalt Wright (Senior Business Development Director)
25.10. Science 37
25.10.1. Interview Transcript: Michael Shipton (Chief Commercial Officer), Darcy Forman (Chief Delivery Officer), Troy Bryenton (Chief Technology Officer), Grazia Mohren (Head of Marketing)
25.11. TrialX
25.11.1. Interview Transcript: Paul Donnelly (Chief Strategy Officer)
25.12. WeGuide
25.12.1. Interview Transcript: Sanji Kanagalingam (Chief Executive Officer)
25.13. Woodley Trial Solutions
25.13.1. Interview Transcript: Hassan Ali (Business Development Manager)
25.14. ConsilX
25.14.1. Interview Transcript: Himanshu Verma (Founder and Chief Executive Officer), Rajesh Jain (Co-Founder)
25.15. EmpiraMed
25.15.1. Interview Transcript: Greg Erman (President and Chief Executive Officer)
26. APPENDIX 1: TABULATED DATA
27. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS